First National Trust Co Lowers Holdings in Eli Lilly and Company (NYSE:LLY)

First National Trust Co decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,411 shares of the company’s stock after selling 624 shares during the quarter. Eli Lilly and Company comprises about 1.1% of First National Trust Co’s investment portfolio, making the stock its 17th biggest holding. First National Trust Co’s holdings in Eli Lilly and Company were worth $27,594,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in LLY. WestEnd Advisors LLC raised its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Citizens National Bank Trust Department raised its stake in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the first quarter worth $40,000. Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $43,000. Finally, O Brien Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after purchasing an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $763.30 on Wednesday. The firm has a market cap of $723.40 billion, a price-to-earnings ratio of 62.11, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The business has a 50-day moving average price of $773.36 and a 200-day moving average price of $800.41. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business’s revenue was up 45.2% on a year-over-year basis. During the same period last year, the company earned $2.58 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 48.82%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Morgan Stanley restated an “overweight” rating and issued a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price objective for the company. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their price objective for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Guggenheim lifted their price objective on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a “buy” rating in a report on Friday, July 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.